Managing HIV lipoatrophy

Lancet. 2004 Feb 7;363(9407):412-4. doi: 10.1016/S0140-6736(04)15521-9.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use
  • Dideoxynucleosides / therapeutic use
  • HIV-Associated Lipodystrophy Syndrome / chemically induced
  • HIV-Associated Lipodystrophy Syndrome / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / prevention & control
  • Human Growth Hormone / therapeutic use
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Metabolic Syndrome / chemically induced
  • Metabolic Syndrome / drug therapy
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Rosiglitazone
  • Stavudine / adverse effects
  • Stavudine / therapeutic use
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • Hypoglycemic Agents
  • Protease Inhibitors
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • Thiazolidinediones
  • Rosiglitazone
  • Human Growth Hormone
  • Stavudine
  • abacavir